JUL 23, 2018 12:20 PM PDT

Targeting a Protein Kinase in Sickle Cell Disease

WRITTEN BY: Nouran Amin

Searching for a drug that may treat sickle cell disease (SCD) blood disorder researchers identified a protein responsible for regulating the production of hemoglobin present in erythrocytes (red blood cells). The identified protein is a signaling molecule and a kinase known as HRI. HRI was seen to regulate the iron-carrying component of blood, hemoglobin. The results of this study were recently published in the scientific journal, Science.

Performing lab tests on cultured human cells revealed that inhibiting HRI resulted in a reduction of the characteristic sickling properties of SCD that cause a distortion of the red blood cell shape ultimately giving the disease its name. "We have found a protein with activity specifically in red blood cells that could be a 'druggable' target, possibly with a small molecule -- a pill that patients could take to treat sickle cell disease," explains study co-leader Gerd A. Blobel, MD, PhD, a scientist at Children's Hospital of Philadelphia (CHOP).

The results of the research study provided evidence of HRI and its role in a unique process known as "hemoglobin switching”; the biochemical transition normally occurring in infants where red blood cells switch from production of a fetal form of hemoglobin to the adult form. Therefore, it is known that the mutation responsible for SCD is actually present in the adult form of hemoglobin, which explains SCD happens to affect patients only after birth.

 

SCD mutation leads to red blood cells becoming abnormally crescent-shaped that clog blood vessels and damages organs; which is painful and life-threatening to affected individuals. The current standard treatment for SCD, prescribed by hematologists, is a hydroxyurea drug that increases fetal hemoglobin. Unfortunately, this treatment is not effective for all patients and so researchers are seeking other options.

Utilizing CRISPR gene-editing techniques, researchers screened a class of domains encompassing protein kinases; enzymes that can be inhibited by a small molecule. This screening method allowed the discovery of HRI, the kinase capable of aiding in the silencing of fetal hemoglobin production in red blood cells. Additionally, these results informed researchers how HRI works to suppress fetal hemoglobin production and how, if inhibiting HRI, can fetal hemoglobin rise.

 

Without altering the viability or maturation of red blood cells, a reduction of “sickling” was achieved on SCD patients, proving that inhibition of HRI function was not a loss. Researchers believe that developing a drug that inhibits HRI might not only be effective for SCD but also as a treatment option for a range of other hemoglobin disorders. "Our long-term goal is to carry out follow-up studies to evaluate whether this approach improves clinical outcomes in patients," said Blobel. "At this point, our results suggest that HRI is a potential target for a new treatment for disorders of hemoglobin."

Source: Children's Hospital of Philadelphia, Science  

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 24, 2019
Drug Discovery & Development
NOV 24, 2019
The unlikely pain killer
Pain can be anything a sunburn, a toothache, or a leg injury to name a few. The relievers that target our pain come in many colors—one being morphine...
NOV 27, 2019
Drug Discovery & Development
NOV 27, 2019
New Painkiller More Effective than Opioids Discovered in Mud
Researchers have discovered a new painkiller dubbed to be as effective as opioids, only minus their disadvantages, from a 16-year old mud sample found near...
DEC 15, 2019
Microbiology
DEC 15, 2019
Potential Therapeutics for Nipah Virus Are Identified
The fatality rate of Nipah virus has an estimated range of 40 to 75 percent...
DEC 16, 2019
Drug Discovery & Development
DEC 16, 2019
Vaccine To Protect Against The Zika Virus
Scientists at The University of Texas Medical Branch at Galveston present for the first time how a single high dose vaccine can protect a pregnant mouse al...
DEC 27, 2019
Microbiology
DEC 27, 2019
Using a Cancer Drug to Fight Antibiotic-Resistant Pathogens
It takes a long time for a drug to be approved for use in humans; repurposing existing drugs is one way to get around that hurdle....
JAN 16, 2020
Health & Medicine
JAN 16, 2020
Babies in Africa Receive World's First Malaria Vaccine
Would you accept a vaccine that was only 40% effective? For those at risk of malaria, the answer is likely a resounding, "yes!" According to the...
Loading Comments...